LivaNova PLC (NASDAQ:LIVN) Shares Purchased by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. raised its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 12.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 504,361 shares of the company's stock after purchasing an additional 57,723 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.93% of LivaNova worth $23,357,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Harbor Capital Advisors Inc. bought a new stake in shares of LivaNova during the 4th quarter worth $1,954,000. KBC Group NV boosted its stake in LivaNova by 130.5% in the fourth quarter. KBC Group NV now owns 99,928 shares of the company's stock worth $4,628,000 after buying an additional 56,580 shares in the last quarter. Rhumbline Advisers lifted its position in LivaNova by 0.5% in the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock valued at $8,240,000 after purchasing an additional 899 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of LivaNova by 2.6% during the fourth quarter. Principal Financial Group Inc. now owns 175,878 shares of the company's stock valued at $8,145,000 after acquiring an additional 4,476 shares in the last quarter. Finally, Paradice Investment Management LLC raised its holdings in shares of LivaNova by 15.3% during the fourth quarter. Paradice Investment Management LLC now owns 486,821 shares of the company's stock valued at $22,545,000 after acquiring an additional 64,680 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research report on Tuesday. Mizuho reduced their price objective on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 26th. Wolfe Research downgraded LivaNova from an "outperform" rating to a "peer perform" rating in a research report on Wednesday, February 26th. Robert W. Baird boosted their price objective on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Finally, The Goldman Sachs Group dropped their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a report on Monday, March 3rd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $59.17.

LivaNova Trading Down 1.2%

LIVN stock traded down $0.51 during midday trading on Wednesday, hitting $43.55. 773,346 shares of the company's stock were exchanged, compared to its average volume of 643,791. The business has a 50-day simple moving average of $38.06 and a two-hundred day simple moving average of $45.03. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $2.37 billion, a PE ratio of 103.69 and a beta of 0.84. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $63.57.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.